Radiotheranostics in oncology: current challenges and emerging opportunities

L Bodei, K Herrmann, H Schöder, AM Scott… - Nature Reviews …, 2022 - nature.com
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer

A Farolfi, L Calderoni, F Mattana, R Mei… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …

E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET

F Ceci, DE Oprea-Lager, L Emmett, JA Adam… - European journal of …, 2021 - Springer
Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2023 - Springer
Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

Appropriate use criteria for prostate-specific membrane antigen PET imaging

H Jadvar, J Calais, S Fanti, F Feng… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Prostate cancer is the most common cancer diagnosis in men in the United States and a
leading cause of cancer-related morbidity and mortality (1). It can exist along a wide …

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

S Fanti, K Goffin, BA Hadaschik, K Herrmann… - European Journal of …, 2021 - Springer
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography
(PET)/computed tomography (CT) is used for (re) staging prostate cancer (PCa) and as a …

TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical …

MS Hofman, L Emmett, J Violet, A Y. Zhang… - BJU …, 2019 - Wiley Online Library
Objective To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment
with 177Lu‐PSMA‐617, a novel radiolabelled small molecule that binds with high affinity to …

Using PSMA imaging for prognostication in localized and advanced prostate cancer

MJ Roberts, T Maurer, M Perera, M Eiber… - Nature Reviews …, 2023 - nature.com
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Prostate-specific membrane antigen–targeted therapies for prostate cancer: towards improving therapeutic outcomes

M Corpetti, C Müller, H Beltran, J de Bono… - European urology, 2024 - Elsevier
Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …

Androgen receptor signaling in prostate cancer and therapeutic strategies

A Jacob, R Raj, DB Allison, ZW Myint - Cancers, 2021 - mdpi.com
Simple Summary Early-stage and castration-sensitive prostate cancer (PCa) growth is solely
mediated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have …